According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Innovative urinary miRNA profiling shows potential for early pancreatic cancer detection, with high accuracy and sensitivity, ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Objective responses included: 2 PRs among 3 MSI-H patients with both responders having pancreatic ductal adenocarcinoma. One patient with MSI-H PDAC was initially misclassified as MSI-H small bowel ...

The gut microbiome's impact on pancreatic cancer highlights potential for early screening and fecal microbiota ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

CD40 agonists have had mixed results in cancer to date, with Roche discontinuing its selicrelumab candidate after ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...